Furthermore, bezafibrate, a pan-agonist for all PPAR isoforms, increases fatty acid β-oxidation, oxidative phosphorylation, glycolysis, and CD8+ T cell survival, and restores CD8+ T cell effector function in combination with anti-PD-L1 therapy in a sarcoma mouse model, via upregulation of carnitine palmitoyltransferase I (CPT1) α and B cell lymphoma 2 (BCL2)28. This evidence concerns the gene CD8A and sarcoma.